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Abstract
Background: Intravenous administration of fluids is an essential part of critical care. While some fluid administration
is likely beneficial, there is increasing observational evidence that the development of fluid overload is associated
with increased mortality. There are no randomised trials to confirm this association in patients with acute kidney
injury. We aim to perform a pilot trial to test the feasibility of forced fluid removal compared to standard care in
patients with acute kidney injury and severe fluid overload, the FFAKI trial.
Methods: Then FFAKI trial is a pilot, multicentre, randomised clinical trial recruiting adult intensive care patients
with acute kidney injury and fluid overload, defined as more than 10% of ideal bodyweight. Patients are randomised
with concealed allocation to either standard care or forced fluid removal with a therapeutic target of negative net fluid
balance ≥1 mL/kg/h. The safety of fluid removal is continually evaluated according to predefined criteria of
hypoperfusion: lactate ≥4 mmol/L, mean arterial pressure <50 mmHg or mottling beyond the edge of the
kneecaps. If patients fulfil one of these criteria, fluid removal is suspended until hypoperfusion has resolved.
The primary outcome measure is fluid balance at 5 days after randomisation and secondary outcomes include
mean daily fluid balance, fluid balance at discharge from the intensive care unit, time to neutral fluid balance,
number of serious adverse reactions and number of protocol violations. All patients are followed for 90 days.
Discussion: The FFAKI trial started in October 2015 and, when completed, will provide data to evaluate whether a
large trial of forced fluid removal in critically ill patients is feasible. Our primary outcome will show if the experimental
intervention leads to a clinically relevant difference in fluid balance, which could prove beneficial in intensive care
patients with acute kidney injury.
Trial registration: EudraCT, identifier: 2015-001701-13. Registered on 19 September 2015;
ClinicalTrials.gov, identifier: NCT02458157. Registered on 21 May 2015;
Danish Ethics Committee, identifier: H-15009589H. Registered on 22 September 2015; Danish Health and Medicines
Authority, identifier: 2015070013. Registered on 11 August 2015.
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Background
Administration of isotonic crystalloid solutions is a
common intervention in critically ill patients. In some
cases this leads to the accumulation of fluids and
development of fluid overload, defined as a positive
fluid balance corresponding to 10% or more of total
bodyweight. The cut-off at 10% was first utilised in a
paediatric observational study by Gillespie et al. [1],
and subsequently adopted in the adult population [2].
Growing observational data have linked fluid overload
to a poor outcome in several different patient popula-
tions including those with acute kidney injury (AKI)
[3]. This was analysed in a recent systematic review
and meta-analysis of data from 12 cohort studies
including 5095 patients [4]. Six of the 12 studies re-
ported adjusted odds ratios (ORs) for death, and the
pooled results associated fluid overload with increased
risk of death with an OR of 2.23 (95% CI, 1.66–3.01)
and a moderate level of heterogeneity (I2 = 62%).
Mean positive daily fluid balance was also shown to
be associated with death with an OR of 1.16 (95% CI,
1.07–1.27); however, there was significant heterogen-
eity amongst the studies (n = 6, I2 = 94%).
The observed association between fluid overload and
outcome may in part be mediated by the development of
interstitial oedema leading to deranged organ architec-
ture, increased diffusion distances for oxygen and
metabolites and increased interstitial pressure [5].
A study in healthy volunteers demonstrated that infusion
of 2 L crystalloid leads to renal swelling [6]. Renal intersti-
tial volume and pressure may be correlated in a nonlinear
manner, suggesting that a ‘renal compartment’ exists [7]
and increased interstitial pressure has been linked to a de-
cline in renal blood flow (RBF), glomerular filtration rate
(GFR) and sodium excretion [8, 9]. The detrimental effect
of fluid overload has been attenuated in experimental renal
decapsulation in both animals and humans [10].
Given the observational nature of the available data,
there is a high risk of confounding by indication and a
causal relationship cannot be established before rando-
mised data are available [11]. We aim to perform a feasi-
bility trial of forced fluid removal in intensive care unit
(ICU) patients with AKI and severe fluid overload. If we
are able to achieve a clinically relevant difference in fluid
balance we believe that a definitive trial powered for
mortality is warranted.
Methods
The FFAKI trial is a multicentre, randomised, site-stratified,
clinical pilot trial with adequate computer generation of the
allocation sequence with permuted blocks of varying size
and allocation concealment. Randomisation is performed
using sequentially numbered, opaque, sealed envelopes.
The trial statistician is blinded but due to the nature
of the intervention it is not possible to blind patients or
caregivers.
The trial is initiated at three separate centres in
Denmark. Each centre has one or two primary investiga-
tors with expert knowledge in the FFAKI intervention
and protocol. Participants in the FFAKI trial will receive
protocol-specific treatment during their entire ICU stay.
Therefore, every caregiver at participating centres
receives training in the protocol by either the principal
investigator or one of the primary investigators. It is ex-
pected that the primary centre (Nordsjællands Hospital)
will include 20–30 patients and each secondary centre
will include 10–15 patients.
The trial protocol was written according to the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Statement [12]. A populated SPIRIT
Checklist and figure are provided in Additional file 1
and Fig. 1, respectively.
Patients
All patients admitted to the ICU at the participating
centres will be eligible for screening according to the
following:
Inclusion criteria
 Age 18 years or older
 AKI defined according to the Kidney Disease
Improving Global Outcomes (KDIGO) criteria [13]
 Renal Recovery Score (RRS) ≤60%
 Fluid overload defined as a positive fluid balance of
at least 10% of ideal body weight
 Able to undergo randomisation within 12 h of
fulfilling the other inclusion criteria
Exclusion criteria
 Known allergy to furosemide or sulphonamides
 Known prehospitalisation advanced chronic kidney
disease (estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m2 or chronic renal replacement
therapy)
 Severe hypoxic respiratory failure (use of invasive
ventilation and fraction of inspired oxygen (FiO2)
>80% and positive end-expiratory pressure (PEEP)
>10 cmH2O)
 Severe burn injury (≥10% total burned surface area)
 Severe dysnatraemia (plasma concentrations <120 or
>155 mmol/L)
 Hepatic coma
 Mentally disabled undergoing forced treatment
 Pregnancy/breastfeeding
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Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure for the FFAKI trial. CONSORT 2010 Flow Diagram
for the FFAKI-trial
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 Lack of commitment for ongoing life support
including renal replacement therapy (RRT)
 Lack of informed consent
Patients who fulfil all of the inclusion criteria and none
of the exclusion criteria will be enrolled in the trial and
allocated to either the experimental treatment (forced
fluid removal) or standard care. Based upon own obser-
vational data we expect that roughly 10% of adult
patients admitted for more than 24 h will be available
for inclusion in the FFAKI trial (Fig. 2).
Forced fluid removal (Figs. 3, 4 and 5)
The experimental intervention is guided by a thera-
peutic goal of average net negative fluid balance
≥1 mL/kg/h and safety variables indicating inadequate
circulation (lactate ≥4 mmol/L or mean arterial pres-
sure (MAP) <50 mmHg or mottling beyond the edge
of the kneecaps).
The therapeutic effect is evaluated at three daily sum-
mary points on the ICU observation charts (06:00, 14:00
and 22:00), while safety variables are evaluated
continuously.
The first choice for fluid removal is diuretic therapy
with furosemide which is continued for a minimum of
8 h. If the therapeutic goal cannot be achieved and
maintained by diuretic therapy it is replaced by fluid
removal with continuous renal replacement therapy
(CRRT).
Resuscitation
During the entire trial, the physiologic response to fluid
removal is monitored with three variables indicating
inadequate circulation. These are:
 Mottling beyond the edge of the kneecaps [14]
 Hypotension (MAP <50 mmHg) resistant to
inotropes and vasopressors
 Plasma lactate ≥4 mmol/L [15]
Mottling and MAP are monitored continuously and
lactate is routinely measured four to six times each day
and on clinical indication.
If one or more signs of inadequate circulation are
present the resuscitation algorithm is started:
 Pause fluid removal
 Give a crystalloid fluid bolus of 250–500 mL
 Re-evaluate circulatory status within 30 min
 Repeat fluid therapy and revaluation until adequate
circulation (lactate <4 mmol/L, MAP >50 mmHg
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram
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and no mottling beyond kneecaps) have been
maintained for minimum 1 h
 Restart fluid removal in 25% reduced dose for a
minimum of 4 h before evaluating effect
Fluid removal is continued until the patient achieves
neutral cumulative fluid balance (±1000 mL), which is
then attempted maintained for the entire duration of
ICU admission.
Standard care
In the control group receiving standard care, there are
no protocolled interventions. Fluid administration and
removal is done at the discretion of the treating clini-
cians. Use of dialysis is encouraged only in the presence
of severe disturbances in fluid, electrolyte and acid-base
balance:
 Hyperkalaemia (p-K+ >6 mmol/L)
 Severe metabolic acidosis attributable to AKI
(pH <7.25 and standard base excess (SBE) below
−10 mmol/L) resistant to intravenously (IV)
administered bicarbonate infusion
 Severe respiratory failure with PaO2/FiO2 < 13 kPa
and bilateral infiltrates/oedema on the chest X-ray
 Aside from these absolute indications, RRT may be
provided in case of progressive azotaemia and blood
urea (BUN) >25 mmol/L
All data are collected in a paper-based Case Research
Form (CRF) and participants are followed for a total of
90 days. The primary outcome of the FFAKI trial is
cumulative fluid balance 5 days after randomisation. All
outcome variables are shown in Table 1. Furthermore,
we will evaluate the safety of the intervention by regis-
tering known serious adverse reactions (SARs) to
furosemide and serious adverse events (SAEs) to fluid
removal including: arrhythmia, ischaemia, vasopressor
use and progression of organ failure as captured in the
daily Sequential Organ Failure Score (SOFA) score.
Monitoring and protocol adhesion
The FFAKI trial is externally monitored according to
Good Clinical Practice (GCP) (EU-Directive-2001/20)
guidelines including monitoring of consents and source
data by external staff.
Protocol adhesion is monitored by the GCP guidelines
on the first five patients in both the intervention and
control arm at each centre and protocol violations are
registered in the CRF of all patients. In case of protocol
Fig. 3 FFAKI algorithm for fluid removal with furosemide Fig. 4 FFAKI algorithm for fluid removal with continuous renal
replacement therapy (CRRT)
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violations the principle investigator will initiate re-
education of participating caregivers.
Statistical analysis
The main objective of the FFAKI trial is to determine
whether the trial intervention is feasible. To capture
this we have decided to examine whether the trial
intervention leads to a clinically relevant difference in
fluid balance after 5 days. This is treated as an
interim outcome and in accordance with the newly
published Consolidated Standards of Reporting Trials
(CONSORT) extension to randomised pilot and feasi-
bility trials [16], we used the standard method of
calculating sample size. By including 50 patients in
the trial we will have the power to show a difference
of 6 L in cumulative fluid balance between groups
with a β value of 0.80 and a two-sided α value of
0.05. The sample size estimation is based upon obser-
vational data of patients fulfilling the FFAKI inclusion
criteria admitted at our ICU in 2012 and 2013 (mean
fluid balance 13.8 L, standard deviation (SD) 7.4 L).
Two complimentary analyses of the primary outcome
will be performed in order to account for attrition due
to death. In the first analysis the subject-specific fluid
balances are modelled in a ‘linear random-effects model’
unconditional on survival status. Difference in fluid
balance 5 days after randomisation will be assessed using
a Wald test. In the second analysis we will estimate the
‘survival average causal effect’ of the intervention using
principal stratification and include a sensitivity analysis
to assess the influence of possible violations of assump-
tions. In both models missing data due to dropout will
be handled using ‘inverse probability weighting’.
All parametric data will be presented as mean (SD)
and compared using Student’s t test. Nonparametric
data will be reported as median (interquartile range
(IQR)) and compared using the Mann-Whitney U
test.
Discussion
The FFAKI trial consists of a complex intervention
that alters the core of current therapy for critically
ill patients. Furthermore, the intervention is designed
to treat an iatrogenic condition (fluid overload). To
our knowledge there are no previous implementa-
tions of forced fluid removal in a randomised clinical
design and we have identified several key areas in
which a trial of forced fluid removal might prove
unfeasible:
1. Patient physiology might not allow early and forced
fluid removal
Table 1 Primary, secondary and exploratory outcomes for the
FFAKI trial
Primary outcome Cumulative fluid balance 5 days after
randomisation
Secondary outcomes Mean daily fluid balance during ICU stay
Cumulative fluid balance during the
entire ICU stay
Time to neutral cumulative fluid balance
Number of patients with one or more
major protocol violations
Accumulated SARs in each intervention
arm during the ICU stay
Exploratory outcomes All-cause mortality at day 90
Days alive and out of hospital within
90 days of follow-up
Days alive without mechanical ventilation
within 90 days of follow-up
Days alive without vasopressor/inotropic
therapy within 90 days follow-up
Days alive without RRT within 90 days
follow-up
Renal recovery at day 90
ICU intensive care unit, RRT renal replacement therapy, SAR serious
adverse reaction
Fig. 5 FFAKI resuscitation algorithm
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Patients who develop AKI and fluid overload are
characterised by severe critical illness, often with
failure of multiple organ systems and they receive a
multitude of interventions including mechanical
ventilation, fluid therapy, antibiotics, vasopressors,
inotropes and dialysis. The underlying condition
further compromises the physiology of the patient
leading to leaky capillaries and loss of intravascular
albumin [17]. Fluid removal by diuretics or CRRT is
done from the intravascular compartment and the
extracorporeal removal of fluids depends upon the
compensatory movement of fluids from the
extravascular compartment to the intravascular
compartment [11]. These factors might oppose
removal of fluids and patients who undergo forced
fluid removal could develop further worsening of
circulatory status leading to discontinuation of fluid
removal according to the safety parameters described
earlier. Previous trials have suggested that fluid
restriction and fluid removal in critical illness is safe
and well tolerated by patients admitted to the ICU. The
FACCT trial [18] showed a difference in fluid
balance of 7 L with restricted fluid therapy in patients
with acute lung injury. Ganter and co-workers
performed fluid removal in 10 critically ill patients
with a mixed medical history [19] and achieved
very large cumulative volumes of fluid removal
ranging from 7.4 to 19.8 L during the course of 72 h
2. The Hawthorne effect might alter the administration
of IV fluids leading to reduced incidence of fluid
overload and abolish the need for forced fluid removal
Fluid overload is an iatrogenic condition that arises
as a consequence of the current practice of fluid
therapy in critical illness. When a trial of forced fluid
removal is initiated there will be an inevitable
increased focus on the indications for fluid
administration and removal. This produces a risk of
a Hawthorne effect leading to less fluid administered
by clinicians which would reduce the incidence of
fluid overload in the given patient population and
abolish the need for a trial of this nature
3. Heterogeneity of the patient population could dilute any
potential effect of the intervention leading to reduced
power and the need for a very large sample size
The baseline chance of recovering renal function
following AKI in the ICU varies with age, gender and
the severity of kidney injury. Patients who have a high
chance of recovering with the current standard of care
will have very little potential benefit of participating in a
trial of new therapeutic interventions. Furthermore,
these patients could dilute the potential effect of a given
intervention and lead to a loss in power and need for
larger sample sizes. We have recently developed a
model to predict the chance of recovering renal
function following AKI in the ICU, which is called the
‘Renal Recovery Score’ (RRS) (not yet published). In the
development and validation of the model we found that
the 20% of patients with the highest chance of
recovering renal function had a RRS value of >64% and
an 80–85% frequency of recovery. To selectively include
patients with a moderate to high risk of persistent renal
injury we will be using a RRS value of <60% as part of
the inclusion criteria
4. Lack of blinding
Due to the nature of the intervention it is not
possible to blind participants, caregivers
administering the intervention or caregivers
administering co-interventions. This introduces a
risk of bias which we will evaluate with fluid therapy
and dialysis data in both treatment arms. To avoid
overly aggressive fluid removal in the control group
we discourage the use of dialysis unless specifically
indicated according to previously described criteria
5. Lack of protocol adherence
Forced fluid removal in critically ill patients with
continued need for vasopressors and inotropes
might seem controversial to some clinicians and it is
uncertain whether our intervention can be
performed with the acceptance of the treating
clinicians. Therefore, we register the frequency of
protocol violations defined as the use of dialysis
outside the recommended indications in the control
group, and cessation of fluid removal before
fulfilment of safety criteria or achievement of neutral
fluid balance in the experimental group
By performing a pilot trial with a primary outcome of
fluid balance 5 days after randomisation we will be able
to evaluate whether the intervention is feasible. Further-
more we will know if it leads to a clinically relevant
difference in fluid balance which would indicate that
implementation of this protocol in a larger sample size
would provide analysable results regarding a causal
relationship between fluid removal and patient-centred
outcomes of renal recovery and survival.
Trial status
The FFAKI trial was initiated in October 2015 and
recruitment is currently ongoing at three different sites.
Additional file
Additional file 1: Populated SPIRIT Checklist. (PDF 130 kb)
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